Cobalis Corp. Completes Patient Dosing In Phase III Clinical Trials For OTC Anti-Allergy Product Candidate

IRVINE, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTC BB: CLSC) a pharmaceutical development company specializing in anti-allergy medications, announced today that the Company has completed the dosing portion of its ten-week twin Phase III Clinical Trials for its anti-allergy medication, PreHistin™. The randomized, double blind, placebo-controlled trials are designed to test the safety and efficacy of pre-seasonal treatment with PreHistin on moderate to moderately severe seasonal ragweed allergy patients.